Literature DB >> 17016821

HLA-class II haplotype associations with ovarian cancer.

Kirsten Kübler1, Peter F Arndt, Eva Wardelmann, Dieter Krebs, Walther Kuhn, Katrin van der Ven.   

Abstract

The development of cancer is a multistep process that is characterized by the accumulation of genetic alterations in cells and changed cellular interactions with the surrounding healthy tissues. The human immune system is believed to be intrinsically involved in this process. The correlation of certain human leukocyte antigen (HLA)-class I and II haplotypes with tumorigenesis is documented in a variety of tumors. However, few data exist on the possible association of specific HLA-class II alleles or haplotypes with ovarian cancer. In our sample of 52 Caucasian patients with primary ovarian carcinoma and 239 female healthy local controls, we observed a significantly increased incidence of the HLA-class II haplotypes DRB1*0301 - DQA1*0501 - DQB1*0201 (p < 0.001) and DRB1*1001 - DQA1*0101 - DQB1*0501 (p < 0.001) in the patients. Our data suggest that HLA-class II loci or individual HLA-class II haplotypes may be involved in the pathogenesis of ovarian cancer. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016821     DOI: 10.1002/ijc.22266

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Selected human leukocyte antigen class II polymorphisms and risk of adult glioma.

Authors:  Bryan A Bassig; Peter D Inskip; Laurie Burdette; William R Shapiro; Robert G Selker; Howard A Fine; Jay S Loeffler; Peter M Black; Robert Dubrow; Alina V Brenner
Journal:  J Neuroimmunol       Date:  2010-12-30       Impact factor: 3.478

2.  Classical HLA alleles are associated with prevalent and persistent cervical high-risk HPV infection in African women.

Authors:  Sally N Adebamowo; Adebowale A Adeyemo
Journal:  Hum Immunol       Date:  2019-05-06       Impact factor: 2.850

3.  Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk.

Authors:  Chenan Zhang; Joseph L Wiemels; Helen M Hansen; Julio Gonzalez-Maya; Alyson A Endicott; Adam J de Smith; Ivan V Smirnov; John S Witte; Libby M Morimoto; Catherine Metayer; Kyle M Walsh
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

4.  HLA-A2 expression, stage, and survival in colorectal cancer.

Authors:  Philipp Kiewe; Veit Mansmann; Carmen Scheibenbogen; Heinz-Johannes Buhr; Eckhard Thiel; Dirk Nagorsen
Journal:  Int J Colorectal Dis       Date:  2008-05-07       Impact factor: 2.571

5.  Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan.

Authors:  Otília Menyhárt; János Tibor Fekete; Balázs Győrffy
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

6.  Pro-inflammatory cytokine polymorphisms and interactions with dietary alcohol and estrogen, risk factors for invasive breast cancer using a post genome-wide analysis for gene-gene and gene-lifestyle interaction.

Authors:  Su Yon Jung; Jeanette C Papp; Eric M Sobel; Matteo Pellegrini; Herbert Yu; Zuo-Feng Zhang
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

7.  In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines.

Authors:  Orsolya Lőrincz; József Tóth; Levente Molnár; István Miklós; Kata Pántya; Mónika Megyesi; Eszter Somogyi; Zsolt Csiszovszki; Enikő R Tőke
Journal:  Cells       Date:  2021-11-05       Impact factor: 6.600

8.  Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.

Authors:  Ronit Mazor; Chin-Hsien Tai; Byungkook Lee; Ira Pastan
Journal:  J Immunol Methods       Date:  2015-06-06       Impact factor: 2.287

9.  Relevance of HLA-DP/DQ and ICAM-1 SNPs among Ovarian Cancer Patients.

Authors:  Amany A Ghazy; Nour M El-Etreby
Journal:  Front Immunol       Date:  2016-05-24       Impact factor: 7.561

10.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.